middle.news
AdAlta Advances 'East to West' Strategy to Revolutionize Solid Cancer Therapies
5:24pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
AdAlta Advances 'East to West' Strategy to Revolutionize Solid Cancer Therapies
5:24pm on Sunday 1st of June, 2025 AEST
Key Points
AdAlta targets three in-licensed Asian cellular immunotherapy assets by end-2025
Focus on T cell therapies for solid cancers with clinical data and manufacturing in Australia
Capital-light, scalable model with rapid value inflection through clinical milestones
AD-214 fibrosis drug candidate available for partnering post Phase I success
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Adalta (ASX:1AD)
OPEN ARTICLE